Clinical Trial Update: Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing efficacy, safety, and pharmacokinetics of MSC2156119J in Asian participants with hepatocellular carcinoma completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MSC2156119J (MSC2156119J)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-24